QUREBIO
QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory cancer, autoimmune diseases, and metabolic diseases in China and the world to benefit patients. QureBio has multiple technology platforms for antibody drug development including phage display technology platforms and hybridoma antibodies technology platform and monoclonal antibody platform. The company was founded in 2017 and is based in Pudong District, Shanghai.
QUREBIO
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2017-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Total Employee:
101+
Status:
Active
Contact:
+86 136 2177 2640
Email Addresses:
[email protected]
Total Funding:
10 M CNY
Similar Organizations
Aprea
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
Bycen
Bycen does Research and development of human and animal behavior.
ComGen Biopharmaceutical
ComGen Biopharmaceutical is a researcher and developer of innovative drugs for immunotherapy of autoimmune diseases and tumors.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Guangdong Guofang Medical Technology
Guangdong Guofang Medical Technology is focused on the research and development of new pharmaceutical excipients.
Gynov
Gynov focuses on the development of innovative solutions dedicated to women's health issues.
HeRui BioMed
HeRui BioMed focuses on the development and industrialization of laboratory diagnostic technology.
Huvet Bio
Huvet Bio is engaged in the research and development of bio pharmaceuticals.
PHI BIOMED
PHI BIOMED offers the research and development of nanomedical and smart biomaterials products in contact lenses, serums, and proteins.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Qiyu Biotech
Qiyu Biotech is an innovative macromolecular drug developer.
Shanghai Henlius Biotech
Shanghai Henlius Biotech is joint venture company that provides clinical-stage biopharmaceutical services.
TechnoDerma Medicines
TechnoDerma Medicines is engaged in the research and development of skin drugs for external use.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Employees Featured
Founder
Investors List
Shenzhen Capital Group
Shenzhen Capital Group investment in Series A - QureBio
More informations about "QureBio"
QureBio - Crunchbase Company Profile & Funding
QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory …See details»
QureBio - Funding, Financials, Valuation & Investors - Crunchbase
QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ...See details»
Q-1801 - Drug Targets, Indications, Patents - Synapse - Patsnap
US FDA Approval of IND for Q-1801 by QureBio.Ltd SHANGHAI, China, Sep 24, 2022-- QureBio Ltd., invested and incubated by Viva BioInnovator, is a clinical-stage biopharmaceutical …See details»
QureBio Ltd. to Present its Q-1802 Clinical PhaseⅡ Data at 2024 …
SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered …See details»
Qure Bio will develop new types of immune cell therapy for solid …
Aug 25, 2021 QureBio was established in July 2017 in Medicine Valley of Zhangjiang, Shanghai Pilot Free Trade Zone. It is an international company focusing on the research and …See details»
The U.S. Food and Drug Administration granted IND …
QureBio recently received tens of millions of A + rounds of financing, and the investor is the Shenzhen Capital Group Company, Ltd. ("SCGC"). This round of financing will mainly be used to advance the pre-clinical development of Q …See details»
IND Approval of Q-1802 from QureBio by FDA - PR …
SHANGHAI, March 1, 2021 /PRNewswire/ -- Feb 27 th, 2021, the U.S. Food and Drug Administration granted IND approval for Q-1802 from QureBio.Ltd. Q-1802 is a bispecific antibody which can target PD ...See details»
The enrollment of the first patient in phase I clinical trials of the ...
June. 18, 2021. The enrollment of the first patient in phase I clinical trials of the first Claudin18.2/PD-L1 bispecific antibody. On June 16, 2021, Qure Bio, as a company dedicated …See details»
QureBio's First Bispecific Antibody Q-1802 Combination Clinical …
April. 12, 2022. QureBio's First Bispecific Antibody Q-1802 Combination Clinical Trial (phase I/II) Was Approved. QureBio announced today that its self-developed bispecific antibody Q-1802 …See details»
QureBio - Crunchbase
QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals.See details»
QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 …
May 31, 2022 QureBio Ltd. has secured a Series-B funding of nearly 200 million CNY. QureBio Ltd. engages in collaboration with partners to develop novel therapeutics for unmet medical …See details»
QureBio Q-1801 Project was approved by CDE - Viva BioInnovator
QureBio announced that its independently developed Q-1801 project received the domestic CDE clinical trial approval notice on January 11, 2023. Previously, the project had received the FDA …See details»
QureBio Completes Series A and Begins to Move into the Clinical …
QureBio is a research and development company focused on innovative biologics. Their goal is to create new drugs that could treat many indications such as cancer, autoimmune, and …See details»
QureBio Q-1801 Project was approved by CDE
Jan 13, 2023 QureBio announced that its independently developed Q-1801 project received the domestic CDE clinical trial approval notice on January 11, 2023. Previously, the project had …See details»
Q-1902 - Drug Targets, Indications, Patents - Synapse - Patsnap
Q-1902, Initially developed by Qurebio Ltd., Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms, Active Indication: Neoplasms, Active Org.: Qurebio Ltd.. …See details»
QureBio's First Bispecific Antibody Q-1802 Combination Clinical …
On April 12, QureBio that invested and incubated by Viva BioInnovator, announced that its self-developed bispecific antibody Q-1802 received a notification of drug clinical trial approval from …See details»
Interim results of a first-in-human phase 1 study of Q-1802, a …
Jan 24, 2023 Background: Q-1802 is a humanized bispecific antibody that targets both the tumor -specific antigen CLDN18.2 and the immune checkpoint PD-L1. Q-1802 monotherapy dose …See details»
QureBio Q-1801 project was approved by FDA
Sep 19, 2022 QureBio announced that its self-developed Q-1801 project has recently received the FDA's approval notice for clinical trials, and is also in the process of China's IND …See details»
Qu Xiangdong - Founder @ QureBio - Crunchbase Person Profile
Qu Xiangdong is the founder of QureBio and has more than 20 years of experience in the development of new drugs at home and abroad. He has worked in world-renowned …See details»
Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients …
Jun 2, 2022 Background: Q-1802 is a humanized bispecific antibody that targets both the tumor -specific antigen CLDN18.2 and the immune checkpoint PD-L1.Methods: This is a first-in …See details»